Close

Catabasis Pharma (CATB) Tops Q3 EPS by 11c

Go back to Catabasis Pharma (CATB) Tops Q3 EPS by 11c

Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights

November 10, 2016 4:10 PM EST

-- Enrollment Complete for MoveDMD® Phase 2 Trial of Edasalonexent, a Potential Disease-Modifying Treatment for Duchenne Muscular Dystrophy (DMD) --

-- Expanding Rare Disease Pipeline with CAT-5571, a Potential Treatment for Cystic Fibrosis --

-- Investor Day Scheduled for November 17 --

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a... More